Identification of new IL-7Rα small-molecule agonists: a multi-computational approach

References

• N. ElKassar and R.E. Gress, An overview of IL-7 biology and its use in immunotherapy, J. Immunotoxicol. 7 (2010), pp. 1–7. doi:https://doi.org/10.3109/15476910903453296.
   PubMed Web of Science ®Google Scholar
• J. Lorenzo, Chapter 9 - The effects of immune cell products (cytokines and hematopoietic cell growth factors) on bone cells, in Osteoimmunology, 2nd, J. Lorenzo, M.C. Horowitz, Y. Choi, H. Takayanagi, and G. Schett, eds., Academic Press, Cambridge, 2016, pp. 143–167.
   Google Scholar
• H. Spits, In interleukin-7, in Encyclopedia of Hormones, H.L. Henry and A.W. Norman, eds., Academic Press, Cambridge, 2003, pp. 439–446.
   Google Scholar
• N. Bosco, F. Agenès, and R. Ceredig, Effects of increasing IL-7 availability on lymphocytes during and after lymphopenia-induced proliferation, J. Immunol. 175 (2005), pp. 162–170. doi:https://doi.org/10.4049/jimmunol.175.1.162.
   PubMed Web of Science ®Google Scholar
• J. Lin, Z. Zhu, H. Xiao, M.R. Wakefield, V.A. Ding, Q. Bai, and Y. Fang, The role of IL-7 in immunity and cancer, Anticancer Res. 37 (2017), pp. 963–967.
   PubMed Web of Science ®Google Scholar
• R. Mazzucchelli and S.K. Durum, Interleukin-7 receptor expression: Intelligent design, Nat. Rev. Immunol. 7 (2007), pp. 144–154. doi:https://doi.org/10.1038/nri2023.
   PubMed Web of Science ®Google Scholar
• A. Sheikh and N. Abraham, Interleukin-7 receptor alpha in innate lymphoid cells: More than a marker, Front. Immunol. 10 (2019), pp. a2897. doi:https://doi.org/10.3389/fimmu.2019.02897.
   PubMedGoogle Scholar
• B.R. Lawson, R. Gonzalez-Quintial, T. Eleftheriadis, M.A. Farrar, S.D. Miller, K. Sauer, D.B. McGavern, D.H. Kono, R. Baccala, and A.N. Theofilopoulos, Interleukin-7 is required for CD4+ T cell activation and autoimmune neuroinflammation, Clin. Immunol. 161 (2015), pp. 260–269. doi:https://doi.org/10.1016/j.clim.2015.08.007.
   PubMed Web of Science ®Google Scholar
• S.L. Silva, A.S. Albuquerque, P. Matoso, B. Charmeteau-de-muylder, R. Cheynier, D. Ligeiro, M. Abecasis, R. Anjos, J.T. Barata, and R.M. Victorino, IL-7-induced proliferation of human naive CD4 T-cells relies on continued thymic activity, Front. Immunol. 8 (2017), pp. a20. doi:https://doi.org/10.3389/fimmu.2017.00020.
   PubMed Web of Science ®Google Scholar
• A. Chahroudi and G. Silvestri, Interleukin-7 in HIV pathogenesis and therapy, Eur. Cytokine Netw. 21 (2010), pp. 202–207.
   PubMed Web of Science ®Google Scholar
• Y. Levy, C. Lacabaratz, L. Weiss, J.-P. Viard, C. Goujard, J.-D. Lelièvre, F. Boué, J.-M. Molina, C. Rouzioux, and V. Avettand-Fénoêl, Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment, J. Clin. Invest. 119 (2009), pp. 997–1007.
   PubMed Web of Science ®Google Scholar
• C. Sportès and R.E. Gress, Interleukin-7 immunotherapy, in Immune-Mediated Diseases. Advances in Experimental Medicine and Biology, M.R. Shurin and Y.S. Smolkin, eds., Springer, New York, 2007, pp. 321–333.
   Google Scholar
• A. Bikker, C.E. Hack, F.P.J.G. Lafeber, and J.A.G. van Roon, Interleukin-7: A key mediator in T cell-driven autoimmunity, inflammation, and tissue destruction, Curr. Pharm. Res. 18 (2012), pp. 1–10. doi:https://doi.org/10.2174/138161212800165979.
   Web of Science ®Google Scholar
• M. Yasunaga, S. Manabe, and Y. Matsumura, Immunoregulation by IL-7R-targeting antibody-drug conjugates: Overcoming steroid-resistance in cancer and autoimmune disease, Sci. Rep. 7 (2017), pp. 1–14. doi:https://doi.org/10.1038/s41598-017-11255-4.
   PubMed Web of Science ®Google Scholar
• J. Gao, L. Zhao, Y.Y. Wan, and B. Zhu, Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy, Int. J. Mol. Sci. 16 (2015), pp. 10267–10280. doi:https://doi.org/10.3390/ijms160510267.
   PubMed Web of Science ®Google Scholar
• C.-H. Yuan, X.-Q. Yang, C.-L. Zhu, S.-P. Liu, B.-C. Wang, and F.-B. Wang, Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model, Asian Pac. J. Cancer Prev. 15 (2014), pp. 265–271. doi:https://doi.org/10.7314/APJCP.2014.15.1.265.
   PubMedGoogle Scholar
• S.A. Rosenberg, C. Sportès, M. Ahmadzadeh, T.J. Fry, L.T. Ngo, S.L. Schwarz, M. Stetler-Stevenson, K.E. Morton, S.A. Mavroukakis, and M. Morre, IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells, J. Immunother. 29 (2006), pp. 313–319. doi:https://doi.org/10.1097/01.cji.0000210386.55951.c2.
   PubMed Web of Science ®Google Scholar
• W. Dummer, A.G. Niethammer, R. Baccala, B.R. Lawson, N. Wagner, R.A. Reisfeld, and A.N. Theofilopoulos, T cell homeostatic proliferation elicits effective antitumor autoimmunity, J. Clin. Invest. 110 (2002), pp. 185–192. doi:https://doi.org/10.1172/JCI0215175.
   PubMed Web of Science ®Google Scholar
• J.E. Bower, P.A. Ganz, N. Aziz, J.L. Fahey, and S.W. Cole, T-cell homeostasis in breast cancer survivors with persistent fatigue, J. Natl. Cancer Inst. 95 (2003), pp. 1165–1168. doi:https://doi.org/10.1093/jnci/djg0019.
   PubMed Web of Science ®Google Scholar
• I. Marković and S.N. Savvides, Modulation of signaling mediated by TSLP and IL-7 in inflammation, autoimmune diseases, and cancer, Front. Immunol. 11 (2020), pp. a1557. doi:https://doi.org/10.3389/fimmu.2020.01557.
   PubMed Web of Science ®Google Scholar
• Y. Song, Y. Liu, R. Hu, M. Su, D. Rood, and L. Lai, In vivo antitumor activity of a recombinant IL7/IL15 hybrid cytokine in mice, Mol. Cancer Ther. 15 (2016), pp. 2413–2421. doi:https://doi.org/10.1158/1535-7163.MCT-16-0111.
   PubMed Web of Science ®Google Scholar
• L. Belarif, C. Mary, L. Jacquemont, H. Le Mai, R. Danger, J. Hervouet, D. Minault, V. Thepenier, V. Nerrière-Daguin, and E. Nguyen, IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates, Nat. Commun. 9 (2018), pp. 1–13. doi:https://doi.org/10.1038/s41467-018-06804-y.
   PubMed Web of Science ®Google Scholar
• C.A. McElroy, J.A. Dohm, and S.T. Walsh, Structural and biophysical studies of the human IL-7/IL-7Rα complex, Structure 17 (2009), pp. 54–65. doi:https://doi.org/10.1016/j.str.2008.10.019.
   PubMed Web of Science ®Google Scholar
• OpenEye Scientific Software, Santa Fe, NM, USA, 2018.
   Google Scholar
• BIOVIA, Dassault systèmes, Pipeline Pilot, San Diego, CA, USA, 2020.
   Google Scholar
• BIOVIA, Dassault systèmes, Discovery Studio, San Diego, CA, USA, 2020.
   Google Scholar
• C. Klein, I. Waldhauer, V.G. Nicolini, A. Freimoser-Grundschober, R. Nayak, D.J. Vugts, C. Dunn, M. Bolijn, J. Benz, and M. Stihle, Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines, Oncoimmunology 6 (2017), pp. e1277306. doi:https://doi.org/10.1080/2162402X.2016.1277306.
   PubMed Web of Science ®Google Scholar
• Desmond Molecular Dynamics System, D. E. shaw research, New York, NY, USA, 2020. Maestro Desmond Interoperability Tools, Schrödinger, New York, NY, USA, 2020.
   Google Scholar
• SpectraMax M5e, Molecular devices, San Jose, CA, USA, 2010.
   Google Scholar
• OriginLab Corporation, Northampton, MA, USA, 2016.
   Google Scholar
• J. Baell and M.A. Walters, Chemistry: Chemical con artists foil drug discovery, Nature 513 (2014), pp. 481–483. doi:https://doi.org/10.1038/513481a.
   PubMed Web of Science ®Google Scholar
• J. Mortier, C. Rakers, M. Bermudez, M.S. Murgueitio, S. Riniker, and G. Wolber, The impact of molecular dynamics on drug design: Applications for the characterization of ligand–macromolecule complexes, Drug Discov. Today 20 (2015), pp. 686–702. doi:https://doi.org/10.1016/j.drudis.2015.01.003.
   PubMed Web of Science ®Google Scholar